Current treatment strategies for inhibiting mTOR in cancer
• We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors.
Gespeichert in:
| Autor*in: |
Chiarini, Francesca [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
12 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Covering the Cover - Chan, Andrew T. ELSEVIER, 2018, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:36 ; year:2015 ; number:2 ; pages:124-135 ; extent:12 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.tips.2014.11.004 |
|---|
| Katalog-ID: |
ELV018281370 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV018281370 | ||
| 003 | DE-627 | ||
| 005 | 20230623142743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tips.2014.11.004 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015005000018.pica |
| 035 | |a (DE-627)ELV018281370 | ||
| 035 | |a (ELSEVIER)S0165-6147(14)00195-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.87 |2 bkl | ||
| 100 | 1 | |a Chiarini, Francesca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current treatment strategies for inhibiting mTOR in cancer |
| 264 | 1 | |c 2015 | |
| 300 | |a 12 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors. | ||
| 650 | 7 | |a dual PI3K/mTOR inhibitors |2 Elsevier | |
| 650 | 7 | |a rapalogs |2 Elsevier | |
| 650 | 7 | |a translation |2 Elsevier | |
| 650 | 7 | |a ATP-competitive mTOR inhibitors |2 Elsevier | |
| 650 | 7 | |a rapamycin |2 Elsevier | |
| 700 | 1 | |a Evangelisti, Camilla |4 oth | |
| 700 | 1 | |a McCubrey, James A. |4 oth | |
| 700 | 1 | |a Martelli, Alberto M. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Chan, Andrew T. ELSEVIER |t Covering the Cover |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV004340590 |
| 773 | 1 | 8 | |g volume:36 |g year:2015 |g number:2 |g pages:124-135 |g extent:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.tips.2014.11.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.87 |j Gastroenterologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 36 |j 2015 |e 2 |h 124-135 |g 12 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
f c fc |
|---|---|
| matchkey_str |
chiarinifrancescaevangelisticamillamccub:2015----:urntetettaeisoihbt |
| hierarchy_sort_str |
2015 |
| bklnumber |
44.87 |
| publishDate |
2015 |
| allfields |
10.1016/j.tips.2014.11.004 doi GBVA2015005000018.pica (DE-627)ELV018281370 (ELSEVIER)S0165-6147(14)00195-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.87 bkl Chiarini, Francesca verfasserin aut Current treatment strategies for inhibiting mTOR in cancer 2015 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors. dual PI3K/mTOR inhibitors Elsevier rapalogs Elsevier translation Elsevier ATP-competitive mTOR inhibitors Elsevier rapamycin Elsevier Evangelisti, Camilla oth McCubrey, James A. oth Martelli, Alberto M. oth Enthalten in Elsevier Science Chan, Andrew T. ELSEVIER Covering the Cover 2018 Amsterdam [u.a.] (DE-627)ELV004340590 volume:36 year:2015 number:2 pages:124-135 extent:12 https://doi.org/10.1016/j.tips.2014.11.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.87 Gastroenterologie VZ AR 36 2015 2 124-135 12 045F 610 |
| spelling |
10.1016/j.tips.2014.11.004 doi GBVA2015005000018.pica (DE-627)ELV018281370 (ELSEVIER)S0165-6147(14)00195-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.87 bkl Chiarini, Francesca verfasserin aut Current treatment strategies for inhibiting mTOR in cancer 2015 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors. dual PI3K/mTOR inhibitors Elsevier rapalogs Elsevier translation Elsevier ATP-competitive mTOR inhibitors Elsevier rapamycin Elsevier Evangelisti, Camilla oth McCubrey, James A. oth Martelli, Alberto M. oth Enthalten in Elsevier Science Chan, Andrew T. ELSEVIER Covering the Cover 2018 Amsterdam [u.a.] (DE-627)ELV004340590 volume:36 year:2015 number:2 pages:124-135 extent:12 https://doi.org/10.1016/j.tips.2014.11.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.87 Gastroenterologie VZ AR 36 2015 2 124-135 12 045F 610 |
| allfields_unstemmed |
10.1016/j.tips.2014.11.004 doi GBVA2015005000018.pica (DE-627)ELV018281370 (ELSEVIER)S0165-6147(14)00195-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.87 bkl Chiarini, Francesca verfasserin aut Current treatment strategies for inhibiting mTOR in cancer 2015 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors. dual PI3K/mTOR inhibitors Elsevier rapalogs Elsevier translation Elsevier ATP-competitive mTOR inhibitors Elsevier rapamycin Elsevier Evangelisti, Camilla oth McCubrey, James A. oth Martelli, Alberto M. oth Enthalten in Elsevier Science Chan, Andrew T. ELSEVIER Covering the Cover 2018 Amsterdam [u.a.] (DE-627)ELV004340590 volume:36 year:2015 number:2 pages:124-135 extent:12 https://doi.org/10.1016/j.tips.2014.11.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.87 Gastroenterologie VZ AR 36 2015 2 124-135 12 045F 610 |
| allfieldsGer |
10.1016/j.tips.2014.11.004 doi GBVA2015005000018.pica (DE-627)ELV018281370 (ELSEVIER)S0165-6147(14)00195-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.87 bkl Chiarini, Francesca verfasserin aut Current treatment strategies for inhibiting mTOR in cancer 2015 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors. dual PI3K/mTOR inhibitors Elsevier rapalogs Elsevier translation Elsevier ATP-competitive mTOR inhibitors Elsevier rapamycin Elsevier Evangelisti, Camilla oth McCubrey, James A. oth Martelli, Alberto M. oth Enthalten in Elsevier Science Chan, Andrew T. ELSEVIER Covering the Cover 2018 Amsterdam [u.a.] (DE-627)ELV004340590 volume:36 year:2015 number:2 pages:124-135 extent:12 https://doi.org/10.1016/j.tips.2014.11.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.87 Gastroenterologie VZ AR 36 2015 2 124-135 12 045F 610 |
| allfieldsSound |
10.1016/j.tips.2014.11.004 doi GBVA2015005000018.pica (DE-627)ELV018281370 (ELSEVIER)S0165-6147(14)00195-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.87 bkl Chiarini, Francesca verfasserin aut Current treatment strategies for inhibiting mTOR in cancer 2015 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors. dual PI3K/mTOR inhibitors Elsevier rapalogs Elsevier translation Elsevier ATP-competitive mTOR inhibitors Elsevier rapamycin Elsevier Evangelisti, Camilla oth McCubrey, James A. oth Martelli, Alberto M. oth Enthalten in Elsevier Science Chan, Andrew T. ELSEVIER Covering the Cover 2018 Amsterdam [u.a.] (DE-627)ELV004340590 volume:36 year:2015 number:2 pages:124-135 extent:12 https://doi.org/10.1016/j.tips.2014.11.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.87 Gastroenterologie VZ AR 36 2015 2 124-135 12 045F 610 |
| language |
English |
| source |
Enthalten in Covering the Cover Amsterdam [u.a.] volume:36 year:2015 number:2 pages:124-135 extent:12 |
| sourceStr |
Enthalten in Covering the Cover Amsterdam [u.a.] volume:36 year:2015 number:2 pages:124-135 extent:12 |
| format_phy_str_mv |
Article |
| bklname |
Gastroenterologie |
| institution |
findex.gbv.de |
| topic_facet |
dual PI3K/mTOR inhibitors rapalogs translation ATP-competitive mTOR inhibitors rapamycin |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Covering the Cover |
| authorswithroles_txt_mv |
Chiarini, Francesca @@aut@@ Evangelisti, Camilla @@oth@@ McCubrey, James A. @@oth@@ Martelli, Alberto M. @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV004340590 |
| dewey-sort |
3610 |
| id |
ELV018281370 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV018281370</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623142743.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.tips.2014.11.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015005000018.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV018281370</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0165-6147(14)00195-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.87</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Chiarini, Francesca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current treatment strategies for inhibiting mTOR in cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">dual PI3K/mTOR inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">rapalogs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">translation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ATP-competitive mTOR inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">rapamycin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Evangelisti, Camilla</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McCubrey, James A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martelli, Alberto M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Chan, Andrew T. ELSEVIER</subfield><subfield code="t">Covering the Cover</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004340590</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:36</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:124-135</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.tips.2014.11.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.87</subfield><subfield code="j">Gastroenterologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">36</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">124-135</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Chiarini, Francesca |
| spellingShingle |
Chiarini, Francesca ddc 610 bkl 44.87 Elsevier dual PI3K/mTOR inhibitors Elsevier rapalogs Elsevier translation Elsevier ATP-competitive mTOR inhibitors Elsevier rapamycin Current treatment strategies for inhibiting mTOR in cancer |
| authorStr |
Chiarini, Francesca |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV004340590 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.87 bkl Current treatment strategies for inhibiting mTOR in cancer dual PI3K/mTOR inhibitors Elsevier rapalogs Elsevier translation Elsevier ATP-competitive mTOR inhibitors Elsevier rapamycin Elsevier |
| topic |
ddc 610 bkl 44.87 Elsevier dual PI3K/mTOR inhibitors Elsevier rapalogs Elsevier translation Elsevier ATP-competitive mTOR inhibitors Elsevier rapamycin |
| topic_unstemmed |
ddc 610 bkl 44.87 Elsevier dual PI3K/mTOR inhibitors Elsevier rapalogs Elsevier translation Elsevier ATP-competitive mTOR inhibitors Elsevier rapamycin |
| topic_browse |
ddc 610 bkl 44.87 Elsevier dual PI3K/mTOR inhibitors Elsevier rapalogs Elsevier translation Elsevier ATP-competitive mTOR inhibitors Elsevier rapamycin |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
c e ce j a m ja jam a m m am amm |
| hierarchy_parent_title |
Covering the Cover |
| hierarchy_parent_id |
ELV004340590 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Covering the Cover |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV004340590 |
| title |
Current treatment strategies for inhibiting mTOR in cancer |
| ctrlnum |
(DE-627)ELV018281370 (ELSEVIER)S0165-6147(14)00195-3 |
| title_full |
Current treatment strategies for inhibiting mTOR in cancer |
| author_sort |
Chiarini, Francesca |
| journal |
Covering the Cover |
| journalStr |
Covering the Cover |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
124 |
| author_browse |
Chiarini, Francesca |
| container_volume |
36 |
| physical |
12 |
| class |
610 610 DE-600 610 VZ 44.87 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Chiarini, Francesca |
| doi_str_mv |
10.1016/j.tips.2014.11.004 |
| dewey-full |
610 |
| title_sort |
current treatment strategies for inhibiting mtor in cancer |
| title_auth |
Current treatment strategies for inhibiting mTOR in cancer |
| abstract |
• We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors. |
| abstractGer |
• We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors. |
| abstract_unstemmed |
• We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
2 |
| title_short |
Current treatment strategies for inhibiting mTOR in cancer |
| url |
https://doi.org/10.1016/j.tips.2014.11.004 |
| remote_bool |
true |
| author2 |
Evangelisti, Camilla McCubrey, James A. Martelli, Alberto M. |
| author2Str |
Evangelisti, Camilla McCubrey, James A. Martelli, Alberto M. |
| ppnlink |
ELV004340590 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.tips.2014.11.004 |
| up_date |
2024-07-06T18:27:23.125Z |
| _version_ |
1803855271692337152 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV018281370</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623142743.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.tips.2014.11.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015005000018.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV018281370</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0165-6147(14)00195-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.87</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Chiarini, Francesca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current treatment strategies for inhibiting mTOR in cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• We delineate the roles of mTOR in the biology of healthy and cancer cells. • We focus on the current therapeutic strategies used to inhibit mTOR. • We highlight the mechanisms of resistance to mTOR inhibitors. • We discuss the major challenges in the clinical use of mTOR inhibitors.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">dual PI3K/mTOR inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">rapalogs</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">translation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ATP-competitive mTOR inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">rapamycin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Evangelisti, Camilla</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McCubrey, James A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martelli, Alberto M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Chan, Andrew T. ELSEVIER</subfield><subfield code="t">Covering the Cover</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004340590</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:36</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:124-135</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.tips.2014.11.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.87</subfield><subfield code="j">Gastroenterologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">36</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">124-135</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4007673 |